ERBB2 and intrahepatic cholangiocarcinoma: The first in-human, multicenter, phase 1 trial reported the safety and tolerability of zanidatamab in patients with locally advanced or metastatic solid tumors, including BTC (intrahepatic cholangiocarcinoma (n = 5), extrahepatic cholangiocarcinoma (n = 4), and gallbladder cancer (n = 13)) with HER2 overexpression or amplification, who had received all available approved therapies [38] (NCT02892123).